Oflomac CX 200 mg/200 mg Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Ofloxacin 200 mg, designed for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death, while Ofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. This synergistic combination enhances antibacterial efficacy against both Gram-positive and Gram-negative pathogens, including respiratory tract infections, urinary tract infections, otitis media, and uncomplicated gonorrhea. Oflomac CX is indicated for patients with mixed infections or infections caused by organisms resistant to monotherapy. The tablet should be administered orally, preferably with food to reduce gastrointestinal discomfort. Dosage and duration of therapy must be guided by the severity of infection and patient-specific factors, including renal function. Caution is advised in patients with a history of hypersensitivity to cephalosporins or fluoroquinolones. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. This combination should not be used in pregnant or lactating women without medical supervision. Proper adherence to prescribed dosage is essential to prevent antibiotic resistance.